AntibodySystem는 Primary Antibody Biosimilar - Research Grade
제품을 전문적으로 생산하는 20년의 경험이 있는 High Quality 제조사입니다.
제품 설명
Research Grade Sotigalimab
제품 번호
DHD68911
제품 특징
The FDA has granted an orphan drug designation to sotigalimab (APX005M) as a potential therapeutic option for patients with soft tissue sarcoma, according to announcement from Apexigen Inc., the drug developer. A novel, humanized monoclonal antibody, sotigalimab was designed stimulate antitumor immune response and to target CD40, which is a key co-stimulatory receptor that serves to activate innate and adaptive immune systems. When sotigalimab binds to CD40 on antigen-presenting cells, it induces a multifaceted immune response that brings several components of the immune system together to attack the cancer.
DHD68911
Humanized
Human
Liquid
0.01M PBS, pH 7.4.
1.7 mg/ml
>95% by SDS-PAGE.
Monoclonal
IgG1-Kappa
Research Grade Biosimilar
Tumor necrosis factor receptor superfamily member 5, B-cell surface antigen CD40, Bp50, CD40L receptor, TNFRSF5, CDw40, CD40
Protein A or G purified from cell culture supernatant.
Please contact with the lab for this information.
XtenCHO
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.Store at +4°C short term (1-2 weeks).Store at -20 °C 12 months. Store at -80°C long term.
APX005M, APX-005, APX-005-M, APX-005M, CAS: 2305607-45-6
For research use only. Not suitable for clinical or therapeutic use.
Data Image
AntibodySystem의 모든 제품들을 만나 보세요!
MSDS
온라인 견적
